| CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma (NCT05458180) | Tianjin Medical University Cancer Institute and Hospital | 2022-07-07 |
| AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27) (NCT06511895) | Dizal Pharmaceuticals | 2022-05-31 |
| Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies (NCT05290155) | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 2022-05-04 |
| Mitoxantrone Hydrochloride Liposomes in Combination With GDP in Relapsed/Refractory PTCL (NCT05441761) | Peking Union Medical College Hospital | 2022-05-01 |
| AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26) (NCT06511869) | Dizal Pharmaceuticals | 2022-03-17 |
| Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2 (NCT05321147) | Innate Pharma | 2022-03-17 |
| PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma (NCT05083208) | Henan Cancer Hospital | 2022-02-20 |
| A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignancies (NCT05269940) | Nanjing Zenshine Pharmaceuticals | 2022-02-17 |
| Study of Lacutamab in Peripheral T-cell Lymphoma (NCT04984837) | The Lymphoma Academic Research Organisation | 2021-10-05 |
| Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL (NCT04052659) | Peking University | 2021-04-15 |
| Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL (NCT04668690) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-04-13 |
| Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies (NCT04828174) | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 2021-03-31 |
| Immune Responses to COVID-19 Vaccination in Lymphoma Patients (NCT04858568) | University Hospital Southampton NHS Foundation Trust | 2021-03-11 |
| PLM60 for Peripheral T Cell Lymphoma (PTCL) (NCT03553914) | Conjupro Biotherapeutics, Inc. | 2021-01-01 |
| Liposomal Mitoxantrone Hydrochloride Injection,Cyclophosphamide, Vincristine and Prednisone in the Treatment of PTCL (NCT04548700) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2020-12-24 |
| Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies (NCT04447027) | National Cancer Institute (NCI) | 2020-12-17 |
| A Study of TQ-B3525 in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma（PTCL） (NCT04615468) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-12-01 |
| The Role of Consolidative Autologous Stem Cell Transplantation After First-line Therapy in Peripheral T Cell Lymphoma (NCT04489264) | Peking University | 2020-11-30 |
| Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma (NCT04512534) | Fudan University | 2020-11-13 |
| A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression (NCT04569032) | Seagen, a wholly owned subsidiary of Pfizer | 2020-11-12 |
| The Efficacy and Safety of F520 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma (PTCL). (NCT04457830) | Shandong New Time Pharmaceutical Co., LTD | 2020-11-01 |
| Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study (NCT04880746) | Ruijin Hospital | 2020-10-17 |
| Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab (NCT04312841) | Ohio State University Comprehensive Cancer Center | 2020-09-15 |
| Evaluate the Safety and Clinical Activity of HH2853 (NCT04390737) | Haihe Biopharma Co., Ltd. | 2020-09-08 |
| A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma (NCT04425070) | Antengene Corporation | 2020-08-18 |
| A Study of SHC014748M in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (NCT04470141) | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 2020-08-01 |
| Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (NCT04480099) | Ruijin Hospital | 2020-07-29 |
| Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy (NCT04480125) | Ruijin Hospital | 2020-06-20 |
| A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer (NCT04254107) | Seagen Inc. | 2020-05-29 |
| A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma (NCT04444141) | Akeso | 2020-05-15 |
| BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I) (NCT04018248) | Boryung Pharmaceutical Co., Ltd | 2020-04-21 |
| Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma" (NCT04213209) | Takeda | 2020-02-14 |
| A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma (NCT04045470) | Dana-Farber Cancer Institute | 2019-12-11 |
| Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides (NCT04101331) | Affimed GmbH | 2019-11-13 |
| A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma (NCT03947255) | Seagen Inc. | 2019-10-28 |
| γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) (NCT04028440) | Institute of Hematology & Blood Diseases Hospital, China | 2019-10-01 |
| CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma (NCT04083495) | UNC Lineberger Comprehensive Cancer Center | 2019-09-17 |
| PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma (NCT04040491) | Mingzhi Zhang | 2019-09-01 |
| Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies (NCT04068597) | CellCentric Ltd. | 2019-08-09 |
| Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies (NCT04008394) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2019-07-03 |
| Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma (NCT03952572) | Peking University | 2019-05-10 |
| Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma (NCT03927105) | University of Michigan Rogel Cancer Center | 2019-04-25 |
| Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma (NCT03719105) | New York Medical College | 2019-03-01 |
| Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas (NCT03586999) | University of Colorado, Denver | 2018-11-07 |
| Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226) (NCT03502629) | Genor Biopharma Co., Ltd. | 2018-07-02 |
| Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma (NCT03553537) | Southwest Hospital, China | 2018-06-01 |
| Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms (NCT03493451) | BeiGene | 2018-04-13 |
| A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) (NCT03372057) | SecuraBio | 2018-02-22 |
| Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects (NCT03629873) | The First Affiliated Hospital with Nanjing Medical University | 2018-02-01 |
| Romidepsin Maintenance After Allogeneic Stem Cell Transplantation (NCT02512497) | Ohio State University Comprehensive Cancer Center | 2017-12-08 |
| Minimal Residual Disease in Peripheral T-cell Lymphoma (NCT03297697) | Washington University School of Medicine | 2017-07-31 |
| Chidamide With CHOP Regimen for de Novo PTCL Patients (CHOP: Cyclophosphamide, Etoposide, Vincristine and Prednisone; PTCL: Peripheral T Cell Lymphoma) (NCT03268889) | The First Affiliated Hospital of Soochow University | 2017-06-15 |
| Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) (NCT03321890) | Sun Yat-sen University | 2017-03-07 |
| Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas (NCT03071822) | The University of Hong Kong | 2017-02-24 |
| Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients (NCT03023358) | Nanfang Hospital, Southern Medical University | 2017-02-01 |
| Effectiveness of Circulating DNA for Predicting the Relapse and Overall Survival in NHL Patients (NCT03079947) | Peking Union Medical College Hospital | 2017-01-01 |
| Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas (NCT02495415) | CerRx, Inc. | 2016-12-01 |
| The Value and Mechanisms for Monocytes Subpopulations in Predicting the Prognosis of Lymphomas (NCT03000738) | Peking Union Medical College Hospital | 2016-12-01 |
| Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma (NCT02856997) | Yuankai Shi | 2016-09-01 |
| A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy (NCT03150602) | Taiwan Mundipharma Pharmaceuticals Ltd. | 2016-08-30 |
| Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients (NCT02809573) | Chipscreen Biosciences, Ltd. | 2016-08-11 |
| Phase I Trial of Selinexor (KPT-330) and Ifosfamide, Carboplatin, Etoposide (ICE) in Peripheral T-cell Lymphoma (NCT03212937) | National Cancer Centre, Singapore | 2016-07-01 |
| Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma (NCT02676778) | Eisai Co., Ltd. | 2016-03-28 |
| A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) (NCT02653976) | Solasia Pharma K.K. | 2016-03-25 |
| Chidamide for Refractory/Relapsed Peripheral T Cell Lymphoma (NCT02944812) | Guangdong Provincial People's Hospital | 2016-03-01 |
| Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma (NCT02753543) | Ruijin Hospital | 2015-11-01 |
| Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL (NCT02445404) | Samsung Medical Center | 2015-09-23 |
| Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma Patients (NCT03141203) | University of Birmingham | 2015-07-13 |
| A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma (NCT01614197) | Therapeutic Advances in Childhood Leukemia Consortium | 2015-07-03 |
| Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma (NCT02232516) | Northwestern University | 2015-06-11 |
| A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors (NCT02440685) | Asana BioSciences | 2015-05-01 |
| Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma (NCT01769911) | Fred Hutchinson Cancer Center | 2015-02-01 |
| Carfilzomib Plus Belinostat in Relapsed/Refractory NHL (NCT02142530) | Massachusetts General Hospital | 2014-10-01 |
| ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas (NCT02264613) | Aileron Therapeutics, Inc. | 2014-10-01 |
| CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma (NCT02168140) | Wake Forest University Health Sciences | 2014-09-01 |
| Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30 (NCT01841021) | H. Lee Moffitt Cancer Center and Research Institute | 2014-04-01 |
| Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant (NCT01959477) | Case Comprehensive Cancer Center | 2014-03-01 |
| Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (NCT02013362) | Mundipharma K.K. | 2014-03-01 |
| Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies (NCT01652014) | University of Medicine and Dentistry of New Jersey | 2014-01-01 |
| MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma (NCT01748721) | Morphotek | 2013-11-01 |
| BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell Lymphomas (NCT07258680) | N.N. Petrov National Medical Research Center of Oncology | 2013-10-01 |
| Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma (NCT01846390) | Canadian Cancer Trials Group | 2013-10-01 |
| Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL) (NCT01839097) | Acrotech Biopharma Inc. | 2013-05-01 |
| Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas (NCT01805037) | Northwestern University | 2013-03-05 |
| Ipilimumab and Local Radiation for Selected Solid Tumors (NCT01769222) | Stanford University | 2013-02-01 |
| Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies (NCT01767766) | TG Therapeutics, Inc. | 2013-01-07 |
| Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients (NCT01822886) | Fondazione Italiana Linfomi - ETS | 2013-01-01 |
| Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma (NCT01796002) | The Lymphoma Academic Research Organisation | 2013-01-01 |
| A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) (NCT01716806) | Seagen Inc. | 2012-10-31 |
| Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant (NCT01588015) | City of Hope Medical Center | 2012-10-29 |
| A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea (NCT01689220) | Solasia Pharma K.K. | 2012-09-01 |
| Phase 1b Safety and Efficacy Study of TRU-016 (NCT01644253) | Aptevo Therapeutics | 2012-09-01 |
| Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL) (NCT01611142) | Kyowa Kirin Co., Ltd. | 2012-04-01 |
| Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT01529827) | Roswell Park Cancer Institute | 2012-02-28 |
| Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies (NCT01427881) | Fred Hutchinson Cancer Center | 2011-09-01 |
| Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients (NCT01420679) | Spectrum Pharmaceuticals, Inc | 2011-08-01 |
| Treatment of Peripheral T-cell Lymphoma (NCT01664975) | Mingzhi Zhang | 2011-08-01 |
| Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma (NCT01336933) | University of Nebraska | 2011-07-06 |
| E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma (NCT01401530) | Eisai Co., Ltd. | 2011-07-01 |
| Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma (NCT01336920) | University of Nebraska | 2011-06-21 |